Key facts
- This page summarizes William Grossman's Form 4 filing for Arcus Biosciences, Inc. (RCUS).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 21 Jun 2021, 16:48.
William Grossman - 16 Jun 2021 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- RCUS
- Reported as of
- 16 Jun 2021
- Net transaction value
- -$168,809
- SEC form
- 4
- Accepted by SEC
- 21 Jun 2021, 16:48:59 UTC
- Next SEC filing
- 19 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carolyn Tang, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
William Grossman filed Form 4 for Arcus Biosciences, Inc. (RCUS) on 21 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$168,809.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RCUS
transaction
Common Stock
Sale
- Transaction value
- $73,524
- Shares
- -3,047
- Change %
- -11%
- Price
- $24.13
- Shares after
- 24,741
- Date
- 16 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F3
RCUS
transaction
Common Stock
Sale
- Transaction value
- $3,146
- Shares
- -127
- Change %
- -0.51%
- Price
- $24.77
- Shares after
- 24,614
- Date
- 16 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F4
RCUS
transaction
Common Stock
Sale
- Transaction value
- $92,139
- Shares
- -3,891
- Change %
- -16%
- Price
- $23.68
- Shares after
- 20,723
- Date
- 17 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Footnote F2
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F3
Includes 1,071 shares purchased on 5/28/2021 through the Company's Employee Stock Purchase Plan
Footnote F4
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.63 to $24.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F5
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.395 to $24.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.